Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objective To evaluate whether amyloid-related imaging abnormalities with edema/effusion (ARIA-E) observed in bapineuzumab clinical trials was associated with specific biomarker patterns. Methods Bapineuzumab, an anti-β-amyloid monoclonal antibody, was evaluated in patients with mild to moderate Alzheimer disease. Amyloid PET imaging, CSF biomarkers, or volumetric MRI (vMRI) were assessed. Results A total of 1,512 participants underwent one or more biomarker assessments; 154 developed incident ARIA-E. No differences were observed at baseline between ARIA-E and non-ARIA-E participants in brain amyloid burden by PET, the majority of vMRI measures, or CSF biomarkers, with the exception of lower baseline CSF Aβ42 in APOE ε4 noncarrier ARIA-E vs non-ARIA-E groups (bapineuzumab non-ARIA-E p = 0.027; placebo non-ARIA-E p = 0.012). At week 71, bapineuzumab-treated participants with ARIA-E vs non-ARIA-E showed greater reduction in brain amyloid PET, greater reductions in CSF phosphorylated tau (p-tau) (all comparisons p < 0.01), and total tau (t-tau) (all comparisons p < 0.025), and greater hippocampal volume reduction and ventricular enlargement (all p < 0.05). Greater reduction in CSF Aβ40 concentrations was observed for ARIA-E versus both non-ARIA-E groups (bapineuzumab/placebo non-ARIA-E p = 0.015/0.049). No group differences were observed at week 71 for changes in whole brain volume or CSF Aβ42. Conclusions Baseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated with significant longitudinal changes in several biomarkers, with larger reductions in amyloid PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases may be related to increased Aβ efflux from the brain and affecting downstream pathogenic processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Self-citationA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Self-citationSchneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512
Self-citationAmyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · cited 2×
“Reduced CSF Aβ42 is a marker of AD pathology and correlates, inversely, with cortical amyloid deposition evaluated by amyloid PET.23,25,26 This APOE gene–dosedependent association is seen in elderly, but not in younger, individuals, irrespective of clinical status, but is not present when stratified for amyloid PET st…”
BackgroundSelf-citationMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401
Cited by
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947
Self-citationAmyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
“13 A β = amyloid-β ; FLAIR = fluid-attenuated inversion recovery; GRE = gradient recalled echo.”
BackgroundKlein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212
“This result contrasts the data reported for bapineuzumab, in which there was a lack of change from baseline in the non-ARIA-E groups [36].”
ResultSelf-citationAmyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi, M., Cecchetti, G., Spinelli, E. G., Vezzulli, P., Falini, A., & Agosta, F. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5205 · Cited by 189
Barakos, J., Purcell, D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo-Viguera, C., Rubino, I., & Vijverberg, E. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.21 · Cited by 165
“developing ARIA-E; however, a lower level of CSF Aβ42, which is indicative of cerebral amyloid accumulation, was observed in ApoE ε4 non-carriers who experienced ARIA-E than in those patients who did not develop ARIA-E (carriers and non-carriers) (38).”
Background
Metadata
- Authors
- Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J., Novak, G., Einstein, S., Booth, K., Ketter, N., Brashear, H. R., For the ELN115727-301/302 Investigator Group, ELN115727-301/302 Investigator Group, Chair, S. S., Sperling, R., Raskind, M., Sabbagh, M., Honig, L., Porsteinsson, A., Ferris, S., Weisman, D., McCartney, M., Iqbal, N., Dietrich, D., Miller, T., Hermann-Gertz, J., Zimmerman, E., Forchetti, C., Dempsey, G. M., Ettigi, P., Jacobson, A., Zacharis, A., Shua-Haim, J., Mehra, V., Markind, S., Zagar, D., Thompson, J., Alva, G., Fuller, W., Rodd, J., Steen, S., Tariot, P., Sabbagh, M., Doody, R., Severa, L., Green, P., Stern, R., McElveen, W., Brody, M., Marshall, G., Seiden, D., Frank, A., Salloway, S., Kinney, F., Litman, R., Soufer, J., Edelsohn, L., Lesem, M., Bernick, C., Kluge, R., Biton, V., DeSantis, M., Wang, X., Usher, G., Morin, C., Omidvar, O., Honig, L., Curtis, C., Licht, J., Coffey, D., Anderson, C., Nash, M., Stein, M., Germain, M., Nair, V., Lippa, C., Beyer, J., Richardson, B., Moore, N., Vidic, T., Igleburger, J., Levey, A., Edwards, K., Steiner, D., Chang, F., Long, J., Turner, R., Apter, J., Barnhart, B., Nash, M., Schwartz, R., Shatz, R., Robillard, A., Garcia, A., Kohlenberg, C., Matthews, B., Chehrenama, H., Garrison, J., Shiwach, R., Jennings, D., Gazda, S., Davtian, A., Booker, J., Rovner, B., Goldenberg, J., Raj, A., Rosenberg, P., Watkins, F., Ingram, J., Chertkow, H., Yadalam, K., Applebaum, J., Biunno, M., Minagar, A., Rujescu, D., Randhawa, S., Dinnerstein, E., Margolin, D., Graff-Radford, N., Knopman, D., Antuono, P., Wilks, K., Du Preez, M., Lichtenstein, T., Barkhuizen, F., Thebaud, A., Liss, J., Mintzer, J., Dal-Bianco, P., Schmidt, R., Gold, S., Farmer, M., Agronin, M., Kohrman, B., Bozoki, A., Kapper, J., Winegarner, D., English, J., Grossman, H., Pomara, N., Murman, D., Spikol, L., Malhotra, S., Biber, M., Burkholder, J., Tramontano, G., Harris, J., Holub, R., Kudrow, D., Honeycutt, W., Waldman, S., Kittur, S., Stein, L., Gerard, G., Cohen, S., Goldstick, L., Chueh, D., Schaerf, F., Nasreddine, Z., Ellis, J., Nash, M., Shubin, R., Gywnn, M., Barker, J., Wendt, J., Mesulam, M., Sadowski, M., Quinn, J., Mikszewski, J., Tuchman, M., Foley, C., Borrie, M., Arnold, S., Rousseau, R., Oskooilar, N., Grosz, D., Wilcox, C., Kwentus, J., Sadowsky, C., Mega, M., Carlini, W., Ranjan, R., Bowman, M., Chakraburtty, A., Nardandrea, J., Sloan, B., Ott, B., Stoukides, J., Keegan, A., Bettinger, I., Grossberg, G., Goldstein, J., Itzcovich-Schuster, J., Winston, J., Feldman, R., Plopper, M., Ferencz, G., Ala, T., Vatakis, N., Montoya, L., Rossen, M., Stedman, M., Pasternak, S., Losk, S., Cohen, S., Ginsberg, P., Ng, B., Au, W., Dolnak, D., Tunell, G., Marotta, G., Ervin, J., Kalafer, M., Solomon, P., Ross, J., Scharre, C., Lobatz, M., Hubbard, R., Lerner, A., Ahern, G., Patry, D., DeCarli, C., Grill, J., Boxer, A., Brewer, J., Preda, A., Mastrianni, J., Burns, J., Jicha, G., Fishman, P., Chopra, A., Barbas, N., Ford, C., Lopez, O., Porsteinsson, A., Smith, A., Auchus, A., Rosenberg, R., Eschweiler, G., Riepe, M., von Arnim, C., Zamrini, E., Dekosky, S., Pendelbury, W., Asthana, S., Hart, D., Raskind, M., Trader, D., Dougherty, J., Vine, D., Carr, D., Tornabene, J., Keren, R., & van Dyck, C.
- Venue
- Neurology
- Published
- 2018-03-06
- Volume
- 90
- Issue
- 10
- Pages
- e877-e886
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2786374432
- Cited by
- 44
- References
- 16
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. https://app.cochat.ai/papers/10.1212/wnl.0000000000005060
- The paper
- Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J., Novak, G., Einstein, S., Booth, K., Ketter, N., Brashear, H. R., For the ELN115727-301/302 Investigator Group, ELN115727-301/302 Investigator Group, Chair, S. S., Sperling, R., Raskind, M., . . . van Dyck, C. (2018). Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology. https://doi.org/10.1212/wnl.0000000000005060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.